APA (7th ed.) Citation

T, O., T, S., I, H., F, S., S, N., H, O., . . . T, S. (2009). Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. Clinical and experimental nephrology, 13(5), 438. https://doi.org/10.1007/s10157-009-0196-0

Chicago Style (17th ed.) Citation

T, Okada, Sakaguchi T, Hatamura I, Saji F, Negi S, Otani H, Muragaki Y, Kawachi H, and Shigematsu T. "Tolvaptan, a Selective Oral Vasopressin V2 Receptor Antagonist, Ameliorates Podocyte Injury in Puromycin Aminonucleoside Nephrotic Rats." Clinical and Experimental Nephrology 13, no. 5 (2009): 438. https://doi.org/10.1007/s10157-009-0196-0.

MLA (9th ed.) Citation

T, Okada, et al. "Tolvaptan, a Selective Oral Vasopressin V2 Receptor Antagonist, Ameliorates Podocyte Injury in Puromycin Aminonucleoside Nephrotic Rats." Clinical and Experimental Nephrology, vol. 13, no. 5, 2009, p. 438, https://doi.org/10.1007/s10157-009-0196-0.